The inflammatory response is mediated by immunological and chemotactic factors, proteins of the complement system, histamine, serotonin, arachidonic acid products and cytokines. All these compounds, including cytokines/chemokines, are major contributors to the symptoms of inflammation. Cytokines/chemokines, commonly referred to as “biological response modifiers”, are relatively new compounds for possible use in stimulation of the immune response, and display a number of overlapping abilities to stimulate cells of various lineages and differentiation stages; nonetheless, most of these compounds are potent inflammatory mediators. Mast cell mediators are either contained within secretory granules or can be synthesized de novo and can be released upon activation by either a massive degranulation, or by a selective release of specific molecules. These cells accumulate in the stroma of a variety of inflamed and transformed tissues in response to locally produced chemotactic factors for immune-cells, such as RANTES and MCP-1. Here we describe some connections between mast cells and chemokines.
OppenheimJJZacharieCOCMukaidaNMatsushimaK. Properties of the novel proinflammatory supergene “Intercrine” cytokine family. Annu Rev Immunol1991; 9:617–23.
Di BonitoPGrassoFManginoG. Immunomodulatory activity of a plant extract containing human papillomavirus 16-E7 protein in human monocyte-derived dendritic cells. Int J Immunopathol Pharmacol2009; 22:967–8.
5.
GordonSTaylorPR. Monocyte and macrophage heterogeneity. Nature Reviews: Immunology2005; 5:953–62.
Di PaolaRCrisafulliCMazzonEGenoveseTPaternitiIBramantiPCuzzocreaS. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice. Int J Immunopathol Pharmacol2009; 22:937–50.
8.
Di LorenzoGMansuetoPPacorML. Clinical importance of eosinophil count in nasal fluid in patients with allergic and non-allergic rhinitis. Int J Immunopathol Pharmacol2009; 22:1077–87.
9.
LevyJA. The unexpected pleiotropic activities of RANTES. J Immunol2009; 182:3945–6.
10.
GibbsBF. Differential modulation of IgE-dependent activation of human basophils by ambroxol and related secretolytic analogues. Int J Immunopathol Pharmacol2009; 22:919–27.
11.
CastellaniMLKempurajDJSaliniV. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents2009; 23:11–14.
12.
LewWOppenheimJJMatsushimaK. Analysis of the suppression of IL-1α and IL-1β production in human peripheral blood mononuclear adherent cells by a glucocorticoid hormone. J Immunol1988; 140:1895–902.
13.
ZuccottiGVTrabattoniDMorelliMBorgonovoSSchneiderLClericiM. Immune modulation by lactoferrin and curcumin in children with recurrent respiratory infections. J Biol Regul Homeost Agents2009; 23:119–24.
14.
CaldarolaGDe SimoneCCarboneATulliAAmerioPFelicianiC. TNFα and its receptors in psoriatic skin, before and after treatment with Etanercept. Int J Immunopathol Pharmacol2009; 22:961–66.
15.
Di LeoEAloiaAMNettisECardinaleFFotiCDistasoMFerranniniAVaccaA. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs. Int J Immunopathol Pharmacol2009; 22:1131–34.
16.
CastellaniMLVecchietJSaliniV. Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance p in LAD2 human mast cells. Tranl Res2009; 154:27–33.
HippeAHomeyBMueller-HomeyA. Chemokines. Recent Results Cancer Res2010; 180:35–50.
19.
D'HaeseJGDemirIEFriessHCeyhanGO. Fractalkine/CX3CR1: Why a single chemokine-receptor duo bears a major and unique therapeutic potential. Expert Opin Ther Targets2010; 14:207–19.
20.
CiardelliLGarofoliFStronatiM. Human colostrum T lymphocytes and their effector cytokines actively aid the development of the newborn immune system. Int J Immunopathol Pharmacol2008; 21:781–6.
21.
GallieraELocatiMMantovaniACorsiMM. Chemokines and bone remodeling. Int J Immunopathol Pharmacol2008; 21:485–91.
22.
ZhuYMWebsterSJFlowerDWollPJ. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer2004; 91:1970–6.
23.
MenniniTGiordanoLMengozziM. Increased IL-8 levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Inflamm2009; 7:39–44.
24.
BleaseKLukacsNWHogaboamCMKunkelSL. Chemokines and their role in airway hyper-reactivity. Respir Res2000; 1:54–61.
25.
OkamotoTIwataSOhnumaKDangNHMorimotoC. Histamine H1-receptor antagonists with immunomodulating activities: Potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin Exp Immunol2009; 157:27–34.
26.
LangerHFChavakisT. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med2009; 13:1211–20.
27.
MoserBWolfMWalzALoetscherP. Chemokines: Multiple levels of leukocyte migration control. Trends in Immunol2004; 25:75–84.
28.
BarkeKEHoughLB. Opiates, mast cells and histamine release. Life Sci1993; 53:1391–9.
29.
Di GioacchinoMPerroneAPetrarcaC. Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol2008; 21:969–76.
30.
HartPH. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol2001; 79:149–53.
31.
TheoharidesTCDonelanJMPapadopoulouNCaoJKempurajDContiP. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci2004; 25:563–8.
32.
GuidaGCullaBScirelliT. Exhaled nitric oxide and nitric oxide synthase expression in Hodgkin's disease. Int J Immunopathol Pharmacol2009; 22:1027–34.
33.
D'AgostoGTrentoENosottiL. CD81 expression on CD19+ peripheral blood lymphocytes is associated with chronic HCV disease and increased risk for HCV infection: A putative role for inflammatory cytokines. J Biol Regul Homeost Agents2009; 23:155–64.
34.
WellsAD. New insights into the molecular basis of T cell anergy: Anergy factors, avoidance sensors, and epigenetic imprinting. J Immunol2009; 182:6088–94.
35.
TheoharidesTCMakrisMKalogeromitrosD. Allergic inflammation and adipocytokines. Int J Immunopathol Pharmacol2008; 21:1–4.
36.
CencioniMTNotturnoFCaporaleCMCreatiBPrencipeVBattistiniLUnciniA. T cell response in acute motor axonal neuropathy. Int J Immunopathol Pharmacol2009; 22:1043–50.
37.
CiprandiGCirilloIPistorioADi GioacchinoMFenoglioD. Ebastine increases IFN-gamma production in patients with persistent allergic rhinitis. J Biol Regul Homeost Agents2009; 23:31–36.
38.
ChurchMKHiroiJ. Inhibition of IgE-dependent histamine release from dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol1987; 90:421–9.
39.
WilmsHRosenstielPRomero-RamosM. Suppression of map kinases inhibits microglial activation and attenuates neuronal cell death induced by α-synuclein protofibrils. Int J Immunopathol Pharmacol2009; 22:897–909.
40.
MurdacaGColomboBMPuppoF. Anti-TNF-alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int J Immunopathol Pharmacol2009; 22:557–65.
41.
ShuvyMBenYa'acovAZolotarovLLotanCIlanY. Beta glycosphingolipids suppress rank expression and inhibit natural killer T cell and CD8+ accumulation in alleviating aortic valve calcification. Int J Immunopathol Pharmacol2009; 22:911–18.
42.
ChibaYSatoSMisawaM. GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma. Int J Immunopathol Pharmacol2009; 22:929–35.
43.
LiQKobayashiMWakayamaYInagakiHKatsumataMHirataYHirataKShimizuTKawadaTParkBJOhiraTKagawaTMiyazakiY. Effect of phytoncide from trees on human natural killer cell function. Int J Immunopathol Pharmacol2009; 22:951–9
ChenQCarrollHPGadinaM. The newest interleukins: Recent additions to the ever-growing cytokine family. Vitam Horm2006; 74:207–28.
46.
BenucciMLi GobbiFSabadiniLSaviolaGBaiardiPManfrediM. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: Cost-effectiveness analysis of sub-cutaneous anti-TNFα treatment in Italian patients. Int J Immunopathol Pharmacol2009; 22:1147–52.
47.
MeazzaCTravaglinoPPaganiSLaarejKDuseMBozzolaM. Hyperimmunoglobulinaemia in babinga pygmies is present from infancy. Int J Immunopathol Pharmacol2009; 22:1117–20
48.
FerraraGLosiMD'AmicoR. Interferon-gamma-release assays detect recent tuberculosis re-infection in elderly contacts. Int J Immunopathol Pharmacol2009; 22:669–78.
NishimuraYMaedaMKumagaiNHayashiHMiuraYOtsukiT. Decrease in phosphorylation of ERK following decreased expression of NK cell activating receptors in human NK cell line exposed to asbestos. Int J Immunopathol Pharmacol2009; 22:879–88.
51.
TarantinoGConcaPTarantinoMDi MinnoMNDGrimaldiEChianeseDRiccioAScopacasaFCaponeD. Does spleen volume play a role in patients with HCV-related chronic hepatitis?Int J Immunopathol Pharmacol2009; 22:1009–17.
52.
SchillaciGRondelliFPirroMBagagliaFPucciGNoyaGMannarinoE. Endothelial progenitor cells are mobilized after major laparotomic surgery in patients with cancer. Int J Immunopathol Pharmacol2009; 22:1035–41.
53.
CantariniLLucheriniOMCimazRBaldariCTBellisaiFPaccaniS RossiPasiniF LaghiCapecchiPLSebastianiGDGaleazziM. Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol2009; 22:1051–8.
54.
AielloFBFurianLMarinoSMarchiniFCardilloMDe FazioNRigottiPValenteM. Acute rejection features in dual kidney transplant recipients from elderly donors: Comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols. Int J Immunopathol Pharmacol2009; 22:1001–7.
55.
TheoharidesTCContiP. Mast cells: The Jekyll and Hyde of tumor growth. Trends Immunol2004; 25:235–41.
56.
CabrelleAMaschioNCarraroS. Apoptotic effect of cyclosporin A and dexamethasone in malignant cells of patients with B-chronic lymphocytic leukaemia. J Biol Regul Homeost Agents2009; 23:239–50.
57.
ColinaMCiancioGGaraviniRContiMTrottaFCovoniM. Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol2009; 22:1125–1129
58.
MarasiniBConciatoLBelloliLMassarottiM. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol2009; 22:573–8.
59.
MarzioniDLorenziTMazzucchelliRCapparucciaLMorroniMFioriniRBracalentiCCatalanoADavidGCastellucciMMuzzonigroGMontironiR. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol2009; 22:627–38.
60.
SessaRDi PietroMSchiavoniGMaconeAMarasBFontanaMZagagliaCNicolettiMDel PianoMMorroneS. Chlamydia pneumoniae induces T cell apoptosis through glutathione redox imbalance and secretion of TNF-alpha. Int J Immunopathol Pharmacol2009; 22:659–68.
61.
CastellaniMLKempurajDSaliniV. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents2009; 23:11–4.
62.
TheoharidesTC. Mast cells and pancreatic cancer. N Engl J Med2008; 358:1860–1.
63.
AmedeiADella BellaCNiccolaiEStanflinNBenagianoMDurantiRDel PreteGMurphyTFD'EliosMM. Moraxella catarrhalis-specific TH1 cells in BAL fluids of chronic obstructive pulmonary disease patients. Int J Immunopathol Pharmacol2009; 22:979–90.
64.
ZampettiAMastrofrancescoAFloriEMarescaVPicardoMAmerioPFelicianiC. Proinflammatory cytokine production in HaCaT cells treated by eosin: Implications for the topical treatment of psoriasis. Int J Immunopathol Pharmacol2009; 22:1067–75
65.
CiprandiGDe AmiciMToscaMAPistorioAMarsegliaGL. Sublingual immunotherapy affects specific antibody and TGF-β serum levels in patients with allergic rhinitis. Int J Immunopathol Pharmacol2009; 22:1089–96.
66.
KalienerMAMetcalfeDD. The Mast Cell in Health and Disease. Ed. Claude Lenfant 199, 62:1–880.
